Servier has announced that it has acquired CTI BioPharma’s non-Hodgkin B-cell lymphoma therapy, Pixuvri (pixantrone).
PARIS--(BUSINESS WIRE)--Servier, an independent international pharmaceutical company, today announced the acquisition of PIXUVRI® from CTI BioPharma. PIXUVRI is a treatment for adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. Servier and CTI Biopharma completed an Asset Purchase Agreement which transferred worldwide rights of PIXUVRI to Servier. Servier commercialized PIXUVRI globally, in all countries where the drug was approved under an exclusive license from CTI BioPharma.
Servier acquires non-Hodgkin B-cell lymphoma treatment PIXUVRI® (pixantrone) from CTI BioPharma, strengthening the Servier oncology portfolio
PARIS--(BUSINESS WIRE)--Servier today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for PIXUVRI® (pixantrone) to convert its conditional approval into a standard marketing authorization as a single agent for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphoma. The CHMP’s opinion will now be sent to the European Commission (EC) for the adoption of the decision.
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche's MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Results of phase iii (PIX306) trial evaluating progression-free survival of Pixuvri® (pixantrone) combined with rituximab in patients with aggressive b-cell non-hodgkin lymphoma. CTI biopharma - pixuvri® plus Rituximab did not show statistically significant improvement in progression-free survival versus gemcitabine plus rituximab.
Seattle-based CTI BioPharma’s $CTIC years-long saga developing Pixuvri (pixantrone) has run into another stone wall. The company reported today that the drug, given conditional approval in Europe 6 years ago, failed a Phase III combination study in B-cell non-Hodgkin lymphoma.